Literature DB >> 20658120

[New therapeutic option for M. Crohn : SONIC study (study of biologic and immunomodulator naive patients in Crohn's disease)].

U R Fölsch1, S Nitschmann.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20658120     DOI: 10.1007/s00108-010-2705-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  4 in total

1.  Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.

Authors:  Ann Corken Mackey; Lanh Green; Li-Ching Liang; Patricia Dinndorf; Mark Avigan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-02       Impact factor: 2.839

2.  [Clinical practice guideline on diagnosis and treatment of Crohn's disease].

Authors:  J C Hoffmann; J C Preiss; F Autschbach; H J Buhr; W Häuser; K Herrlinger; W Höhne; S Koletzko; C F Krieglstein; W Kruis; H Matthes; G Moser; M Reinshagen; G Rogler; S Schreiber; A G Schreyer; B Sido; B Siegmund; A Stallmach; B Bokemeyer; E F Stange; M Zeitz
Journal:  Z Gastroenterol       Date:  2008-09-22       Impact factor: 2.000

3.  Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.

Authors:  Josh Marehbian; H Michael Arrighi; Steve Hass; Haijun Tian; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2009-06-16       Impact factor: 10.864

4.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

Authors:  Gert Van Assche; Charlotte Magdelaine-Beuzelin; Geert D'Haens; Filip Baert; Maja Noman; Séverine Vermeire; David Ternant; Hervé Watier; Gilles Paintaud; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.